GSK’s new chief executive announced plans to narrow the focus of the group’s drug research by ditching 30-plus projects to improve returns in its core pharma business.

The supply of life-saving medicines in Europe could be severely disrupted unless Britain successfully negotiates a smooth and orderly exit from the EU, pharmaceutical industry leaders warned.

Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.

Summit Therapeutics is about to start pivotal tests of a novel antibiotic discovered by UK scientists to treat a sometimes deadly bowel infection, but Britons could be the last patients to get it after Britain leaves the EU.

Romania wants Brussels to relocate its pan-European drug regulator EMA to Bucharest from London after Brexit, the government said.

The Dutch government joined several other EU states in bidding to become the host country of the European Medicines Agency (EMA) once Britain leaves the bloc.

Ireland is the latest candidate to lure the European Medicines Agency should the EMA uproot from London after Britain’s vote to leave the European Union.

Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.